TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03257059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: Glutinous rice (75 grams of available carbohydrate)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Breakfast
Description: No food to be served in the morning
Study: NCT02214134

Intervention type: GENETIC
Intervention: Tumour markers testing

Intervention type: GENETIC
Intervention: Tumour markers testing

Intervention type: GENETIC
Intervention: Tumour markers testing
Study: NCT02275234

Intervention type: OTHER
Intervention: Psychological intervention
Description: Psychological support via clinic visit, helpline and telephone calls
Study: NCT01577888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave System Treatment
Description: Shockwave System Treatment during vascular disease intervention.
Study: NCT02357368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Description: DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant (Eng-Implant)
Description: A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (Lng-IUD)
Description: A standard Mirena IUD will be placed at study week 3 by a trained clinician.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ParaGard® T 380A Intrauterine Copper Contraceptive
Description: A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.
Study: NCT01871935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Anaesthesia with remifentanil/propofol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Anaesthesia with sufentanil/propofol
Study: NCT04082793

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy with mandibular exercises
Description: Low-level laser therapy (BMI 1005 Laser 2200) Wavelength: 658 nm Power: 100 MW Energy density: 4J/cm2 Dose administered: 4J Mode: Pulsed Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions/week on alternating days for 12 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement of the jaw Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetitions X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy with mandibular exercises
Description: Low-level laser therapy (BMI 1005 Laser 2200) Wavelength: 658 nm Power: 100 MW Energy density: 4J/cm2 Dose administered: 4J Mode: Pulsed Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions/week on alternating days for 12 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement of the jaw Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetitions X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sonophoresis with mandibular exercises
Description: Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel Frequency: 1.0 MHz Mode: Continuous Intensity: 0.8 to 1.5 W/cm2~Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions per week on alternating days for 8 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetition X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sonophoresis with mandibular exercises
Description: Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel Frequency: 1.0 MHz Mode: Continuous Intensity: 0.8 to 1.5 W/cm2~Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions per week on alternating days for 8 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetition X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day
Study: NCT03831750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Reduction Intervention
Description: The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.
Study: NCT03895840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilretta
Description: Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.
Study: NCT03074240

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPB Group
Description: Subjects allocated to the TAPB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RSB Group
Description: Subjects allocated to the RSB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conversion to general anesthesia
Description: For those who do not respond to TAPB or RSB to allow for completion of the intended procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conversion to general anesthesia
Description: For those who do not respond to TAPB or RSB to allow for completion of the intended procedure.
Study: NCT04040387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare Therapeutic System
Description: A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NightWare
Description: NightWare device not providing interventions
Study: NCT03382353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Description: Daily consumption of Tramiprosate (100 mg) for 1 year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Description: Daily consumption of Tramiprosate (100 mg) for 1 year

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational training
Description: 16 educational lessons (twice a week): basic principles of different cognitive domains (e.g. memory, attention, perception) and educational DVD viewing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling on a brain-healthy diet
Description: 4 lessons on the principles of Mediterranean Diet lead by a nutritionist, aimed to teach how to include brain-healthy foods in daily diet (e.g. antioxidant, omega-3 fatty acids and vitamins). Each participant will receive the educational material presented.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling on a brain-healthy diet
Description: 4 lessons on the principles of Mediterranean Diet lead by a nutritionist, aimed to teach how to include brain-healthy foods in daily diet (e.g. antioxidant, omega-3 fatty acids and vitamins). Each participant will receive the educational material presented.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise training
Description: 80 sessions of physical exercise supervised by a Fitness Training Expert with the aim of achieving 150 minutes of moderate-intensity physical activity per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: 16 cognitive training sessions (twice a week) supervised by a psychologist, aimed to improve Attention, Processing speed, Memory, Social skills and Intelligence using BrainHQ (www.brainhq.com).
Study: NCT00048074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 2mg iv every 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 2.5mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3mg iv every 3 months
Study: NCT01732289

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genes
Description: Draw blood for genetic screening
Study: NCT02640287

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood or bone marrow samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood or bone marrow samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood or bone marrow samples
Study: NCT02629900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
Study: NCT02124785

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: At Years 21 to 25 after their second vaccine dose.
Study: NCT00770172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study: NCT01239693

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IFA
Description: Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MMN
Description: Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS
Description: Women during pregnancy: 1 sachet of LNS-P\&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P\&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
Study: NCT02991040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revanesse Ultra+ (with lidocaine)
Description: Bilateral nasolabial fold trial to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine) to Revanesse® Ultra (comparator)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revanesse Ultra
Description: Comparator without lidocaine
Study: NCT02129127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Coated Chocolate Balloon Angioplasty
Description: Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
Study: NCT00575731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight management strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight management strategies
Study: NCT03829202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Own mechanical knee
Description: Daily use of own mechanical knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Own mechanical knee
Description: Daily use of own mechanical knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RheoKnee microprocessor prosthetic knee
Description: Daily use of RheoKnee microprocessor prosthetic knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RheoKnee microprocessor prosthetic knee
Description: Daily use of RheoKnee microprocessor prosthetic knee
Study: NCT01192191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg
Description: Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg
Description: Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
Study: NCT01131832

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01286480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-based Educational Intervention
Description: This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
Study: NCT02973750

Intervention type: PROCEDURE
Intervention: Baseline Biopsy
Description: Baseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.

Intervention type: PROCEDURE
Intervention: Tissue Collection
Description: Tissue collection during debulking surgery.

Intervention type: PROCEDURE
Intervention: Blood Draws
Description: Blood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.
Study: NCT01587924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEPO
Description: injection
Study: NCT00993967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone
Description: Idebenone 1350 mg/d, patients \< or equal 45 kg Idebenone 2250 mg/d, patients \> 45 kg
Study: NCT02444078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training will take place in the NH, twice weekly, around 60 minutes per session (session duration can be shorter during the first weeks of intervention according with participants' physical capacity), during 6 months; interval between two exercise sessions will be of at least 48 hours. The exercise program will be a multicomponent training, with exercises specifically developed to improve participants' flexibility (10 minutes), coordination and balance (10 minutes), muscle toning (10 minutes), and cardiorespiratory capacity (25 minutes). The exercise intensity targeted will be moderate. All exercise sessions will be accompanied by music.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social Activity
Description: Interventionists will be health professionals external to the NH, preferentially psychologists. Interventions will take place in the NHs, at the same frequency and duration than the exercise intervention (twice weekly, 60 minutes per session, during 6 months).
Study: NCT00460616

Intervention type: DRUG
Intervention: Cabergoline
Description: According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
Study: NCT03399188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiome transplantation
Description: Fecal microbiota transplantation will be performed through colonoscopy to the IBD patients. Donor feces will be extensively screened for other diseases. Colonoscopy will be done at FMT center of Severance Children's Hospital twice with a month of duration. Recipients will be admitted the day before colonoscopy, and they will be discharged after a day of observation.
Study: NCT02728687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Apply cream as needed up to 4 times daily to the painful foot and leg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthol
Description: Apply cream as needed up to 4 times daily to the painful foot and leg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol
Description: Apply cream as needed up to 4 times daily to the painful foot and leg
Study: NCT01658319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxyamine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies
Study: NCT01578369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise classes with pelvic floor muscle training
Description: Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
Study: NCT02354053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to Triumeq

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence support + current ART

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence support + current ART
Study: NCT00068419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01483261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy
Description: 15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
Study: NCT03135496

Intervention type: OTHER
Intervention: Study of endothelial function biological markers
Description: Study of endothelial function biological markers

Intervention type: OTHER
Intervention: Study of endothelial function biological markers
Description: Study of endothelial function biological markers
Study: NCT01804127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
Study: NCT00891943

Intervention type: OTHER
Group type: OTHER
Intervention: Structured lifestyle support
Description: The intervention group will meet with a research nurse on 14 occasions over the 1 year research study, for structured lifestyle support, including dietary, physical activity and behavioral advice. They will also receive a pedometer.
Study: NCT00763880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
Study: NCT01632722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, mFOLFOX, FOLFIRI
Description: ArmA (postoperative arm)~Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, mFOLFOX, FOLFIRI
Description: ArmB (perioperative arm)~Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)~Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)
Study: NCT00684918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax
Description: A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
Study: NCT04961684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solver Pen
Description: One application per day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loceryl 5%
Description: One application per week for 3 months